UA97953C2 - Стабілізовані поліпептиди інсуліноподібного фактора росту - Google Patents

Стабілізовані поліпептиди інсуліноподібного фактора росту

Info

Publication number
UA97953C2
UA97953C2 UAA200814196A UAA200814196A UA97953C2 UA 97953 C2 UA97953 C2 UA 97953C2 UA A200814196 A UAA200814196 A UA A200814196A UA A200814196 A UAA200814196 A UA A200814196A UA 97953 C2 UA97953 C2 UA 97953C2
Authority
UA
Ukraine
Prior art keywords
growth factor
polypeptide
factor polypeptides
igf
stabilized insulin
Prior art date
Application number
UAA200814196A
Other languages
English (en)
Russian (ru)
Inventor
Девід Джонатан Гласс
Мара Форнаро
Original Assignee
Новартіс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97953(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартіс Аг filed Critical Новартіс Аг
Publication of UA97953C2 publication Critical patent/UA97953C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Винахід належить до поліпептиду, що включає модифікований людський білок-попередник IGF-1, який містить IGF-1 та пептид Е, у якому залишки G1, P2 та E3 видалені, амінокислота в положенні 37 має заміну R37A, а також видалені залишки у положеннях 71 та 72. Винахід також належить до нуклеїнової кислоти, що кодує зазначений поліпептид, вектора, клітини-хазяїна, застосування даного поліпептиду для виготовлення лікарського засобу для лікування захворювань, опосередкованих IGF-1.
UAA200814196A 2006-06-09 2007-06-06 Стабілізовані поліпептиди інсуліноподібного фактора росту UA97953C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24
PCT/US2007/070468 WO2007146689A2 (en) 2006-06-09 2007-06-06 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
UA97953C2 true UA97953C2 (uk) 2012-04-10

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200814196A UA97953C2 (uk) 2006-06-09 2007-06-06 Стабілізовані поліпептиди інсуліноподібного фактора росту

Country Status (32)

Country Link
US (4) US8343918B2 (uk)
EP (2) EP2032155B1 (uk)
JP (2) JP2009539805A (uk)
KR (1) KR101459789B1 (uk)
AR (1) AR061242A1 (uk)
AU (2) AU2007257936B2 (uk)
BR (2) BRPI0712147A2 (uk)
CA (2) CA2654944C (uk)
CL (1) CL2007001614A1 (uk)
CR (2) CR10432A (uk)
CY (1) CY1116117T1 (uk)
DK (2) DK2032155T3 (uk)
EC (1) ECSP088949A (uk)
ES (1) ES2529261T3 (uk)
GT (1) GT200800273A (uk)
HR (1) HRP20150326T1 (uk)
IL (1) IL195156A (uk)
JO (1) JO2968B1 (uk)
MA (1) MA30503B1 (uk)
MX (2) MX2008015726A (uk)
MY (1) MY147856A (uk)
NO (2) NO20085184L (uk)
NZ (2) NZ572548A (uk)
PE (1) PE20080715A1 (uk)
PL (1) PL2032155T3 (uk)
PT (1) PT2032155E (uk)
RU (1) RU2477287C2 (uk)
SI (1) SI2032155T1 (uk)
TN (1) TNSN08509A1 (uk)
TW (1) TWI427084B (uk)
UA (1) UA97953C2 (uk)
WO (2) WO2007141309A2 (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2356148A2 (en) * 2008-11-10 2011-08-17 Novartis AG Antibodies to modified human igf-1/e peptides
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
US8759299B2 (en) * 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
US20120321595A1 (en) 2009-11-09 2012-12-20 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
AU2012220558A1 (en) 2011-02-23 2013-08-22 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012178146A1 (en) * 2011-06-24 2012-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of spinal muscular atrophy
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
EP3626735A1 (en) * 2012-12-18 2020-03-25 Novartis AG Stabilized insulin-like growth factor polypeptides
CN104884467A (zh) 2012-12-18 2015-09-02 诺华股份有限公司 在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
CA2918300A1 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
BR112016005716A2 (pt) * 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
ES2872998T3 (es) 2013-12-19 2021-11-03 Puretein Bioscience Llc Procedimientos de tratamiento de animales
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
EP3253405A4 (en) * 2015-02-04 2018-07-04 Puretein Bioscience, LLC Methods for increasing performance characteristics in offspring
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
SI3600415T1 (sl) 2017-03-24 2026-01-30 Novartis Ag Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) * 2022-01-31 2023-11-01 國立大學法人信州大學 以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞
CN119569848A (zh) * 2024-11-22 2025-03-07 福建省农业科学院畜牧兽医研究所 一种鸭源igf2重组蛋白及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
WO1995032003A1 (en) 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
IL158418A0 (en) * 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AU2006203882B2 (en) * 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP1868637A1 (en) 2005-03-18 2007-12-26 UCL Business PLC Mechano growth factor peptides and their use
US20090271875A1 (en) 2005-03-31 2009-10-29 Pioneer Corporation Upgrade Module, Application Program, Server, and Upgrade Module Distribution System
US8343918B2 (en) 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides

Also Published As

Publication number Publication date
AU2007257936B2 (en) 2011-05-26
CL2007001614A1 (es) 2008-08-08
US8722621B2 (en) 2014-05-13
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
CA2653781A1 (en) 2007-12-13
ECSP088949A (es) 2009-01-30
NZ572548A (en) 2011-06-30
WO2007141309A3 (en) 2008-05-29
JP5290966B2 (ja) 2013-09-18
CA2654944A1 (en) 2007-12-21
IL195156A0 (en) 2011-08-01
RU2008151511A (ru) 2010-07-20
NZ572708A (en) 2011-11-25
TWI427084B (zh) 2014-02-21
DK2032155T3 (en) 2015-03-02
BRPI0712147A2 (pt) 2012-02-22
ES2529261T3 (es) 2015-02-18
BRPI0712052A2 (pt) 2012-01-10
PT2032155E (pt) 2015-04-07
JP2009539805A (ja) 2009-11-19
AU2007255419A1 (en) 2007-12-13
CA2654944C (en) 2017-01-03
KR101459789B1 (ko) 2014-11-07
EP2032154A2 (en) 2009-03-11
AR061242A1 (es) 2008-08-13
JO2968B1 (en) 2016-03-15
KR20090027197A (ko) 2009-03-16
CR10432A (es) 2009-01-15
PE20080715A1 (es) 2008-07-25
RU2477287C2 (ru) 2013-03-10
EP2032155B1 (en) 2014-12-24
EP2032155A2 (en) 2009-03-11
MY147856A (en) 2013-01-31
US20140235538A1 (en) 2014-08-21
MA30503B1 (fr) 2009-06-01
NO20085184L (no) 2009-03-03
US20130059779A1 (en) 2013-03-07
CY1116117T1 (el) 2017-02-08
US20100234290A1 (en) 2010-09-16
CR20160115A (es) 2016-06-14
WO2007146689A3 (en) 2008-04-10
WO2007146689A9 (en) 2010-12-16
US8343918B2 (en) 2013-01-01
IL195156A (en) 2014-07-31
PL2032155T3 (pl) 2015-05-29
TW200835698A (en) 2008-09-01
WO2007146689A2 (en) 2007-12-21
US20100173839A1 (en) 2010-07-08
JP2009539383A (ja) 2009-11-19
NO20085183L (no) 2009-03-09
WO2007141309A2 (en) 2007-12-13
TNSN08509A1 (en) 2010-04-14
HK1126429A1 (en) 2009-09-04
MX2008015726A (es) 2008-12-19
GT200800273A (es) 2009-09-16
DK200900016A (da) 2009-01-06
HRP20150326T1 (hr) 2015-04-24
AU2007257936A1 (en) 2007-12-21
SI2032155T1 (sl) 2015-04-30

Similar Documents

Publication Publication Date Title
EP3204410B1 (en) Biphasic single-chain insulin analogues
AU2013337250B2 (en) Long-acting single-chain insulin analogues
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
HRP20150326T1 (hr) Stabilizirani polipeptidi faktora rasta nalik na inzulin
EP2476699A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
JP2013515055A5 (uk)
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
JP2015504052A5 (uk)
AU2013337250A1 (en) Long-acting single-chain insulin analogues
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2008020968A8 (en) Recombinant interferon-beta with enhanced biological activity
WO2008068428A3 (fr) Utilisation cosmétique de protéines de type chitinase
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
AR029130A1 (es) Gen enzimatico y sus productos de expresion
WO2008029138A3 (en) Peptides and methods
WO2003025182A1 (fr) Adn de surexpression d'une hormone de croissance et utilisation
WO2008103746A3 (en) Production of recombinant insulin-like growth factor-i (igf-i) and insulin-like growth factor binding protein-3 (igfbp-3) in transgenic monocots
HK40045373A (en) Long-acting single-chain insulin analogues
WO2003087375A8 (en) Cartilage differentiation regulating gene
NZ594603A (en) Hybrid polypeptides with selectable properties